ArticleFrontiers in oncology2026
Could iodine be the missing micronutrient in breast cancer development?
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is posing a serious threat to the health of the female workforce as one of the most prevalent malignancies. Emerging epidemiological evidence suggests that insufficient intake of the trace element, iodine, is associated with breast oncogenesis. In this paper, we propose a potential link between iodine deficiency and increased breast cancer risk. A central element of this mechanism may involve the cytoplasmic mislocalization and oncogenic function of the sodium/iodide symporter (NIS), which primarily mediates iodine transport under physiological conditions in the human body. We propose a three-stage model: (1) Initiation: Iodine deficiency triggers systemic alterations in the hypothalamic-pituitary-thyroid (HPT) and gonadal (HPG) axes, as well as lactogenic signaling, establishing a proliferative and inflamed breast microenvironment. (2) Heterogeneous subtype-specific evolution: For hormone receptor-positive (HR+) breast cancer, sustained PI3K/AKT activation driven by the relative dominance of estrogen disrupts normal glycosylation, leading to the cytoplasmic retention of NIS. For triple-negative breast cancer,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.